



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Solitomab

Cat. No.:	HY-P99592
CAS No.:	1005198-65-1
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer ^{[1][2]} .
In Vitro	<p>Solitomab (1 µg/mL; 4 hours) shows cytotoxicity to EpCAM-positive cell lines and increases the sensibility of EpCAM positive carcinosarcomas (CS) cells to T-cell-cytotoxicity^[1].</p> <p>Solitomab (7 days) increases the expression level of CD25 and HLA-DR protein (T-cell activation markers) on CD8⁺ and CD4⁺ T cells^[1].</p> <p>Solitomab (0-2.5 µg/mL; 4 hours) is cytotoxic to ovarian carcinoma cells and the 1 µg/mL dose shows the best tumor killing effects^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Ferrari F, et al. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE[®]), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J Exp Clin Cancer Res. 2015 Oct 17;34:123.

[2]. English DP, et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 2015 Feb 1;121(3):403-12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA